JAHA: Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and cardiovascular outcomes in patients with type 2 diabetes
knee injury after 2 years: Results from the Longitudinal Study (KICK) of the Kennedy Knee Injury Cohort
The latest phase 2 results of NASH's innovative therapies are announced, significantly reducing the level of fibrosis biomarkers
Diabetologia: Long-term use of metformin in patients with type 2 diabetes is associated with the risk of pneumonia and related deaths
Beixi 2 may be difficult to solve the "thirst" of Europe
Determination method of quinolone drug residue analysis technology (2)
China Plastic Price Index (September 2-8)
of alcohol a day can reduce the risk of type 2 diabetes by half?
New discovery: COVID-19 infection + 2 doses of vaccine = super immunity, can fight many mutations
: a double-blind, randomized, placebo-controlled phase 2 trial
with anti-CD20 after being vaccinated with SARS-CoV-2 mRNA vaccine
The chemical sector is advancing vigorously-the performance inventory and outlook of the petroleum and chemical sector in the first half of the year (part 2)
Tetracycline residue analysis technology-pretreatment method (2)
Kanghong has developed a market of over 2 billion!
GUT: Alternative Therapy for Type 2 Diabetes: Medication or Endoscopic Duodenal Mucosal Remodeling?
Painless patients double oral multi-mechanism migraine therapy within 2 hours, expected to be approved next year
Notice of the video defense review meeting for 2 national key R&D plans
or gastroesophageal junction cancer: 2-year updated results of phase III clinical study KEYNOTE-061
It is reported that Longbai Group will submit a form to the Hong Kong Stock Exchange as soon
in the treatment of stage IV non-small cell lung cancer in the form of an oral report at the 2021 World Lung Cancer Conference